BACKGROUND: The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree of toxicity in patients with recurrent sex cord-stromal tumors of the ovary. METHODS: A prospective, multi-institutional cooperative group trial was performed in women with recurrent, measurable ovarian stromal tumors. Patients were allowed to have unlimited prior therapy, excluding bevacizumab. Bevacizumab 15 mg/kg was administered intravenously on day 1 of every 21-day cycle until patients developed disease progression or adverse effects that prohibited further treatment. The primary endpoint was the response rate (RR). Inhibin A and B levels were measured before each cycle, and the values were examined in relation to response and progression. RESULTS: Thirty-six patients were enrolled, and all were eligible and evaluable. Patients received a median of 9 cycles of treatment (range, 2-37 cycles). Six patients (16.7%) had partial responses (90% confidence interval, 7.5%-30.3%), 28 patients (77.8%) had stable disease, and 2 patients (5.6%) had progressive disease. This met the criterion for declaring the regimen active. The median progression-free survival was 9.3 months, and the median overall survival was not reached in during reporting period. Two grade 4 toxicities occurred, including hypertension and proteinuria; and the most common grade 3 toxicities were hypertension (n = 5) and pain (n = 5). Inhibin A and B values were lower in patients who responded to treatment. CONCLUSIONS: Bevacizumab has activity in the treatment of recurrent sex cord-stromal tumors of the ovary, and its toxicity is acceptable. Further investigation is warranted.
BACKGROUND: The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree of toxicity in patients with recurrent sex cord-stromal tumors of the ovary. METHODS: A prospective, multi-institutional cooperative group trial was performed in women with recurrent, measurable ovarian stromal tumors. Patients were allowed to have unlimited prior therapy, excluding bevacizumab. Bevacizumab 15 mg/kg was administered intravenously on day 1 of every 21-day cycle until patients developed disease progression or adverse effects that prohibited further treatment. The primary endpoint was the response rate (RR). Inhibin A and B levels were measured before each cycle, and the values were examined in relation to response and progression. RESULTS: Thirty-six patients were enrolled, and all were eligible and evaluable. Patients received a median of 9 cycles of treatment (range, 2-37 cycles). Six patients (16.7%) had partial responses (90% confidence interval, 7.5%-30.3%), 28 patients (77.8%) had stable disease, and 2 patients (5.6%) had progressive disease. This met the criterion for declaring the regimen active. The median progression-free survival was 9.3 months, and the median overall survival was not reached in during reporting period. Two grade 4 toxicities occurred, including hypertension and proteinuria; and the most common grade 3 toxicities were hypertension (n = 5) and pain (n = 5). Inhibin A and B values were lower in patients who responded to treatment. CONCLUSIONS:Bevacizumab has activity in the treatment of recurrent sex cord-stromal tumors of the ovary, and its toxicity is acceptable. Further investigation is warranted.
Authors: Jubilee Brown; Hyun S Shvartsman; Michael T Deavers; Thomas W Burke; Mark F Munsell; David M Gershenson Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: Nadeem R Abu-Rustum; Antonella Restivo; Joseph Ivy; Robert Soslow; Paul Sabbatini; Yukio Sonoda; Richard R Barakat; Dennis S Chi Journal: Gynecol Oncol Date: 2006-03-13 Impact factor: 5.482
Authors: Jubilee Brown; Anil K Sood; Michael T Deavers; Ljiljana Milojevic; David M Gershenson Journal: Gynecol Oncol Date: 2009-01-21 Impact factor: 5.482
Authors: Kris Ann P Schultz; Anne K Harris; Dominik T Schneider; Robert H Young; Jubilee Brown; David M Gershenson; Louis P Dehner; D Ashley Hill; Yoav H Messinger; A Lindsay Frazier Journal: J Oncol Pract Date: 2016-10 Impact factor: 3.840
Authors: Jane L Meisel; David M Hyman; Anjali Jotwani; Qin Zhou; Nadeem R Abu-Rustum; Alexia Iasonos; Malcolm C Pike; Carol Aghajanian Journal: Gynecol Oncol Date: 2014-12-26 Impact factor: 5.482
Authors: Elizabeth R Burton; Mark Brady; Howard D Homesley; Peter G Rose; Toshiaki Nakamura; Joshua P Kesterson; Jacob Rotmensch; J Tate Thigpen; Linda Van Le Journal: Gynecol Oncol Date: 2015-11-23 Impact factor: 5.482